Key findings
- In vitro the peptide showed balanced activity at the glucagon and GLP-1 receptors but more activity at the GIP receptor, which the authors describe as a triple agonist profile rather than an equipotent one. [1]
- In obese mice the authors attributed the body weight change to two separable contributions: an increase in energy expenditure mediated by the glucagon receptor added to a reduction in calorie intake driven by the GIP and GLP-1 receptors. [1]
- In db/db mice the peptide lowered expression of pro-inflammatory and pro-fibrotic markers in the kidney more than a GLP-1 receptor agonist or a dual agonist comparator, while it did not lower blood glucose more than those comparators. [2]
- In rodent tumor models the peptide delayed tumor onset and reduced tumor volume relative to controls, with immune changes that included raised circulating IL-6 and more antigen presenting cells. [3]
Identity and structure
Mechanism as studied
The discovery report separates the contribution of each receptor. In vitro the peptide was balanced between the glucagon and GLP-1 receptors and more active at the GIP receptor; in obese mice the authors assigned the increase in energy expenditure to the glucagon receptor and the reduction in calorie intake to the GIP and GLP-1 receptors, so that the two contributions add. [1]
Rodent kidney work proposes a different pathway for the renal observations, reporting lower expression of TNF-alpha, caspase-1 and NLRP3 together with lower fibronectin, alpha-smooth muscle actin and collagen I, and a higher content of the intestinal metabolite butyrate, which the authors read as inflammatory and fibrotic mediators plus gut microbiota acting together. [2]
In the rodent tumor work the authors describe systemic and tumor-microenvironment immune reprogramming, with raised circulating IL-6, more antigen presenting cells, fewer immunosuppressive cells and activation of pro-inflammatory pathways, and report that the anti-tumor observation persisted after the peptide was withdrawn and weight was regained. [3]
Research findings
- System
- Receptor activity assays at the glucagon receptor, the GIP receptor and the GLP-1 receptor
- Measured
- Relative agonist activity at each of the three receptors
- Reported
- Activity was balanced between the glucagon and GLP-1 receptors and greater at the GIP receptor. [1]
- System
- Obese mice; the material is the peptide as prepared by its originators rather than a catalog lot
- Measured
- Body weight, glycemic control, energy expenditure and calorie intake
- Reported
- Body weight fell and glycemic control improved; the weight change combined a glucagon receptor mediated increase in energy expenditure with a GIP and GLP-1 receptor driven reduction in calorie intake. [1]
- System
- Db/db mice, compared head to head with liraglutide and with tirzepatide
- Measured
- Body weight, blood glucose, serum biochemistry, renal function, renal inflammation and fibrosis markers, and intestinal butyrate content
- Reported
- Body weight and renal function measures improved more than with either comparator, and renal TNF-alpha, caspase-1, NLRP3, fibronectin, alpha-smooth muscle actin and collagen I expression fell; blood glucose did not fall further than with the comparators. [2]
- System
- Mouse pancreatic and lung tumor models under obesity conditions, with semaglutide as a single-agonist comparator
- Measured
- Tumor engraftment, time to tumor onset, tumor volume, and circulating and tumor-microenvironment immune markers
- Reported
- Engraftment was reduced and onset delayed; tumor volume fell 14-fold in the pancreatic model against a 4-fold reduction with the single agonist, and 17-fold in the lung model relative to controls, alongside raised circulating IL-6 and more antigen presenting cells. [3]
- System
- Male and female rats in an operant drug discrimination procedure; this peptide was given acutely as one of three comparators
- Measured
- Discriminative stimulus effects of alcohol
- Reported
- Acute exposure attenuated alcohol discrimination, as did the two comparator peptides in the same procedure. [4]
Handling for in-vitro work
Open questions
- A cryo-EM structure of this peptide at the three receptors has been published, but no abstract is indexed for it, so no structural row is written here from a source that was read.
- The cited rodent work uses several different genetic backgrounds and challenges, and does not establish which of the three receptors the renal and tumor observations depend on.
- None of the cited work reports an analytical identity check that would distinguish this peptide from a related multireceptor analogue in a supplied lot.
Most of the published literature on this peptide is clinical and concerns a finished formulation; it is out of scope for a research material profile.
Lot records
Check the record for the exact material you order. A published paper and a batch certificate answer different questions.
- RV-24-0006-3 ↗Retatrutide · 99.10% HPLC2026-09-22
- RV-24-0006-2 ↗Retatrutide · 99.10% HPLC2026-09-16
- RV-24-0006-1 ↗Retatrutide · 99.10% HPLC2026-09-16
References
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell metabolism. 2022.
- Ma J, Hu X, Zhang W, et al. Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. Endocrine. 2025.
- Marathe SJ, Grey EW, Bohm MS, et al. Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression. npj metabolic health and disease. 2025.
- Windram M, Lovelock DF, Carew JM, et al. Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats. Psychopharmacology. 2026.
Publication records fetched from PubMed on 2026-09-20. Profile text reviewed 2026-09-20.